Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

PR Newswire associated2

Tags

DualityBio-ASCO-Meet

More Like This

PR Newswire associated0

First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA